A large-scale trial of a new drug shows it boosts survival chances for Hodgkin’s lymphoma, a cancer of the blood that mostly strikes younger people, a study said Thursday. Known by the lab name of brentuximab vedotin (BV), the drug is the first new treatment for Hodgkin’s in more than three decades. Hodgkin’s lymphoma is the commonest blood cancer among people aged 15 to 35. Doctors reporting in the journal The Lancet Diabetes & Endocrinology tested the drug among 329 cancer patients who were at high risk of relapse after stem-cell transplant.
from Health News Headlines - Yahoo News
http://ift.tt/1MQLoIJvia Lazahealth.org
No comments:
Post a Comment